Patents by Inventor Kiflai Bein

Kiflai Bein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Analogs of 2-Pralidoxime as Antidotes Against Organophosphorus Nerve Agents
    Publication number: 20210317084
    Abstract: Provided herein are compounds useful in treating exposure to an organophosphorus compound, such as a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, such as sarin. Compositions, e.g. pharmaceutical compositions or dosage forms, comprising the compounds also are provided herein. Methods of treating a patient exposed to a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, e.g., an organophosphorus compound, such as sarin, also are provided.
    Type: Application
    Filed: May 30, 2019
    Publication date: October 14, 2021
    Inventors: Kazunori Koide, Kiflai Bein, George D. Leikauf, Robert Kruger Bressin, James Proviano Burrows, Adriana Gambino, Dianne Pham
  • Peptide inhibitor of MMP activity and angiogenesis
    Patent number: 6667388
    Abstract: The present invention is directed to peptides that interacts with thrombospondin 2 and inhibit matrix metalloproteinase 9 (MMP-9) activity. Consequently, the invention provides peptides that inhibit MMP-9 activity and are useful as inhibitors of angiogenesis and metastasis, among other diseases regulated by MMP-9. The peptides of the invention and their methods of use are therapeutic against diseases, such as cancer and arthritis, which are characterized by neovascularization.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: December 23, 2003
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Kiflai Bein, Michael Simons
  • Peptide inhibitor of MMP activity and angiogenesis
    Publication number: 20020159989
    Abstract: The present invention is directed to peptides that interacts with thrombospondin 2 and inhibit matrix metalloproteinase 9 (MMP-9) activity. Consequently, the invention provides peptides that inhibit MMP-9 activity and are useful as inhibitors of angiogenesis and metastasis, among other diseases regulated by MMP-9. The peptides of the invention and their methods of use are therapeutic against diseases, such as cancer and arthritis, which are characterized by neovascularization.
    Type: Application
    Filed: January 22, 2001
    Publication date: October 31, 2002
    Inventors: Kiflai Bein, Michael Simons